Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drug
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
3don MSN
A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...
3don MSN
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Eli Lilly & Co.’s fourth-quarter revenue fell ... Demand for Lilly’s obesity and diabetes drugs Zepbound and Mounjaro, which are essentially the same drug, skyrocketed over the past two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback